Given the role played by DCs and T cells in tumour immunity, the current engineering strategies for DC cancer vaccines and ACT should include inhibitors against immune suppressive cytokines, checkpoint ligands, and other suppressive factors such as IDO and ARG-1. Here, IDO1 is linked to neoplasm.